Mobile website
Anti CD3 monoclonal antibody activated autologous killer cells in treatment of advanced malignant tumor: an observation of short term effectiveness
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To investigate the therapeutic effects of anti CD3 monoclonal antibody activated autologous killer cells (CD3AK) in treatment of advanced malignant tumors and their influence on the immune function of patients.Methods: Fifty five patients with solid tumors and 12 with lymphoma, who were admitted to the Qianfoshan Hospital, Shandong University, were treated with CD3AK cells. IL 2 and CD3 Ab were used to induce autologous CD3AK cells from the peripheral blood mono nuclear cells (PBMC) from 67 patients. T cells subsets and the level of NK cells（CD16 +CD56 +）were determined before and after the treatment. Results: The effective rate of autologous CD3AK cells was 2545% for the solid tumors and the clinical beneficial rate was 74.54%; the effective rate was 83.33% for lymphoma and the clinical beneficial rate was 91.67%. The CD8 +cell subsets was decreased after treatment（ P <0.05); the CD3 +，CD4 +cell subsets and CD4 +/CD8 + ratio were significantly increased（ P <0.05）after one course of treatment with CD3AK cells. Conclusion: Autologous CD3AK cells can improve the unbalanced T cell subsets in patients with advanced malignant tumors, upgrade the quality of life of patients, and effectively control tumor growth, with better safety and without adverse effect.
Keywords:
Project Supported:
Supported by the Natural Science Foundation of Shandong Province（No.2005ZX04）
Clc Number:
